Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose versus two-dose BNT162b2 COVID-19 vaccination in previously infected children aged 5-11 years
NL-OMON54453Phase 2Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Aug 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tozinameran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Primary immunogenicity endpoint. Started Aug 2022; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON54453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54453.